TransMedics Group (NASDAQ:TMDX) Trading Down 6.5%

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) were down 6.5% on Tuesday . The company traded as low as $146.10 and last traded at $146.86. Approximately 492,816 shares traded hands during trading, a decline of 40% from the average daily volume of 826,797 shares. The stock had previously closed at $157.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TMDX shares. Oppenheimer raised their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Morgan Stanley boosted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Needham & Company LLC began coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price for the company. Canaccord Genuity Group boosted their price target on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Stephens raised their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Buy” and a consensus price target of $174.30.

TransMedics Group Stock Down 7.2 %

The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The firm has a 50-day moving average of $156.42 and a 200 day moving average of $132.63. The stock has a market capitalization of $4.86 billion, a price-to-earnings ratio of -432.71 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same period last year, the business earned ($0.03) EPS. The business’s revenue was up 117.7% on a year-over-year basis. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director James R. Tobin sold 20,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the transaction, the director now directly owns 173,146 shares in the company, valued at approximately $27,587,352.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director James R. Tobin sold 20,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the sale, the director now owns 173,146 shares in the company, valued at approximately $27,587,352.18. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock worth $9,650,880 in the last three months. 7.00% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $372,000. Teachers Retirement System of The State of Kentucky acquired a new position in TransMedics Group in the second quarter valued at approximately $420,000. NewEdge Advisors LLC grew its holdings in shares of TransMedics Group by 26.0% during the second quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after purchasing an additional 2,140 shares during the last quarter. Creative Planning raised its position in shares of TransMedics Group by 78.3% during the 2nd quarter. Creative Planning now owns 9,173 shares of the company’s stock worth $1,382,000 after purchasing an additional 4,027 shares during the period. Finally, Algert Global LLC acquired a new stake in TransMedics Group in the second quarter worth $2,685,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.